AbCellera Biologics Inc (ABCL)
2.715
-0.16
(-5.73%)
USD |
NASDAQ |
Nov 05, 16:00
2.715
0.00 (0.00%)
After-Hours: 18:57
AbCellera Biologics Enterprise Value: 178.28M for Nov. 4, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 04, 2024 | 178.28M |
| November 01, 2024 | 134.08M |
| October 31, 2024 | 134.08M |
| October 30, 2024 | 148.81M |
| October 29, 2024 | 163.55M |
| October 28, 2024 | 181.23M |
| October 25, 2024 | 131.13M |
| October 24, 2024 | 125.24M |
| October 23, 2024 | 148.81M |
| October 22, 2024 | 166.49M |
| October 21, 2024 | 145.87M |
| October 18, 2024 | 175.33M |
| October 17, 2024 | 119.35M |
| October 16, 2024 | 101.67M |
| October 15, 2024 | 83.99M |
| October 14, 2024 | 72.20M |
| October 11, 2024 | 92.83M |
| October 10, 2024 | 66.31M |
| October 09, 2024 | 63.36M |
| October 08, 2024 | 86.93M |
| October 07, 2024 | 104.61M |
| October 04, 2024 | 66.31M |
| October 03, 2024 | 60.41M |
| October 02, 2024 | 60.41M |
| October 01, 2024 | 86.93M |
| Date | Value |
|---|---|
| September 30, 2024 | 95.77M |
| September 27, 2024 | 98.72M |
| September 26, 2024 | 83.99M |
| September 25, 2024 | 48.63M |
| September 24, 2024 | 72.20M |
| September 23, 2024 | 60.41M |
| September 20, 2024 | 92.83M |
| September 19, 2024 | 137.03M |
| September 18, 2024 | 139.97M |
| September 17, 2024 | 134.08M |
| September 16, 2024 | 119.35M |
| September 13, 2024 | 139.97M |
| September 12, 2024 | 119.35M |
| September 11, 2024 | 122.29M |
| September 10, 2024 | 89.88M |
| September 09, 2024 | 36.84M |
| September 06, 2024 | 33.89M |
| September 05, 2024 | 45.68M |
| September 04, 2024 | 72.20M |
| September 03, 2024 | 66.31M |
| August 30, 2024 | 83.99M |
| August 29, 2024 | 75.15M |
| August 28, 2024 | 83.99M |
| August 27, 2024 | 98.72M |
| August 26, 2024 | 122.29M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
33.89M
Minimum
Sep 06 2024
15.55B
Maximum
Dec 11 2020
2.617B
Average
1.705B
Median
Jan 24 2022
Enterprise Value Benchmarks
| Grace Therapeutics Inc | 12.38M |
| Aurinia Pharmaceuticals Inc | 700.49M |
| Edesa Biotech Inc | 6.305M |
| Lexaria Bioscience Corp | 27.17M |
| InMed Pharmaceuticals Inc | -3.330M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -36.93M |
| Revenue (Quarterly) | 7.323M |
| Total Expenses (Quarterly) | 97.47M |
| EPS Diluted (Quarterly) | -0.13 |
| Profit Margin (Quarterly) | -504.3% |
| Earnings Yield | -19.89% |
| Normalized Earnings Yield | -19.89 |